Genzada Pharmaceuticals   Report issue

For profit Phase 1
Founded: Sterling KS United States (2010)

Organization Overview

First Clinical Trial
2019
NCT03775525
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Genzada Pharmaceuticals USA, Inc.

Active Ingredients

Drugs in Phase 1 Trials (1)

gz17-6.02 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 1)

Carcinoma, Basal Cell (Phase 1)

Carcinoma, Squamous Cell (Phase 1)

Lymphoma (Phase 1)

Lymphoma, T-Cell (Phase 1)

Lymphoma, T-Cell, Cutaneous (Phase 1)

Squamous Cell Carcinoma of Head and Neck (Phase 1)

Stomach Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 1